IQVIA, formerly Quintiles IMS Holdings, Inc., is an American multinational company serving the combined industries of health information technologies and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Hospital

IQVIA

Dr. Mack is responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina’s career at IQVIA has included several leadership roles, all focused on the use of real-world evidence to improve patient care and patient outcomes. Prior to her appointment, Christina served as vice president of Epidemiology and Clinical Evidence, where she led the development of real-world evidence platforms for infectious diseases, medical devices, and sports injury studies. Christina also developed scientific research protocols under an agile analytics model conceived for the avian influenza pandemic, which were used to accelerate the understanding of COVID-19 diagnosis, transmission, and clinical course.

Dr. Mack’s multi-disciplinary skills span technology and science. Christina holds an undergraduate degree in Computer Science Engineering from the University of Notre Dame, as well as a Master of Science in Public Health and a PhD in Epidemiology from the University of North Carolina at Chapel Hill. Dr. Mack co-chairs numerous industry committees and is an adjunct associate professor at the UNC-Chapel Hill School of Public Health. Dr. Mack also serves on the advisory board of the Carolina Health Informatics Program, the ISPE Real World Evidence task force, and co-chairs the Medical Device Epidemiology Network Scientific Oversight Committee.

Christina Mack

John M. Leonard, M.D. has served as a director of [IQVIA](/org/iqvia) since October 2016. Prior to this, Dr. Leonard served as a director of Quintiles from February 5, 2015. Since July 2014, Dr. Leonard has served as the Chief Medical Officer at Intellia Therapeutics, Inc., a biotechnology company involved in gene-based therapy. He previously served as the Chief Scientific Officer and Senior Vice President of Research and Development at [AbbVie](/org/abbvie) Inc., a global pharmaceutical company, from its spin-out from Abbott Laboratories in January 2013 until retiring from those positions at the end of 2013. Prior to the formation of [AbbVie](/org/abbvie), Dr. Leonard served as Senior Vice President of Global Pharmaceutical Research and Development at Abbott from 2008 to 2012. He has over 30 years of combined experience in medicine, research and management, including serving in various roles at Abbott beginning in 1992. Dr. Leonard also serves as a director of Chimerix, Inc., a biopharmaceutical company. He completed an Internship and Residency in Internal Medicine at Stanford University Hospital followed by a Postdoctoral Fellowship in Molecular Virology at the National Institute of Allergy and Infectious Diseases at the [National Institutes of Health](/org/national-institutes-of-health). Dr. Leonard has a bachelor’s degree in Biochemistry from the University of Wisconsin at Madison and a Doctorate in Medicine from [Johns Hopkins University](/org/johns-hopkins-university) in Baltimore, MD. He completed an Internship and Residency in Internal Medicine at Stanford University Hospital followed by a Postdoctoral Fellowship in Molecular Virology at the National Institute of Allergy and Infectious Diseases at the [National Institutes of Health](/org/national-institutes-of-health). Dr. Leonard serves as a member of the Audit Committee and as a member of the Nominating and Governance Committee.


John M. Leonard

Trudy Stein is the EVP and Chief Human Resources Officer at [IQVIA](/org/iqvia). Trudy has over 25 years of experience in Human Resources, including positions at IMS Health, CIT, and Pfizer Pharmaceuticals. Trudy has a proven track record of supporting executives and employees through mergers and acquisitions, as well as leading HR teams through periods of change.

Trudy Stein has a Bachelor of Science in Management from [St. Cloud State University](/org/st-cloud-state-university).

Trudy Stein works with Chris Smyth - President - [IQVIA](/org/iqvia) Biotech, Jovan Willford - SVP, US Commercial Solutions, and Brian Mi - President - APAC. Trudy Stein reports to Ari Bousbib, Chairman & CEO.

Trudy Stein

Bhavik Patel is President of the Commercial Solutions global business unit at IQVIA. He is responsible for advancing the growth of the company’s commercial portfolio, as well as driving innovation for our customers’ commercial ecosystems. Leveraging IQVIA’s Connected Intelligence approach, Commercial Solutions build fit-for-purpose offerings to support launch planning and execution, marketing and promotion, as well as customer and patient engagement, all designed to improve healthcare outcomes. 
 
Bhavik has more than 15 years of service at IQVIA. In this time he has held several key roles in commercial functions ranging from sales leadership to general management both regionally and globally. His focus has always been on driving customer engagements, identifying new market opportunities, and launching innovative offerings. 
 
Most recently, Bhavik served as Senior Vice President, Global Market Insights and MedTech, responsible for the growth of the company’s global market measurement information assets and providing overall leadership for the IQVIA MedTech organization. 
 
Prior to joining IQVIA, he began his career in the healthcare industry at Schwarz Pharma in 2003, where he was responsible for sales to healthcare professionals.

Bhavik Patel

Kevin Knightly is President, Corporate Strategy and Enterprise Networks at IQVIA, where he is responsible for evolving the analytics infrastructure and the associated sourcing and production required to support our products and services. In addition, Kevin is also responsible for aligning the company’s corporate strategy and marketing activities to communicate our integrated value proposition to our customers.

Kevin previously served as president, Technology and Commercial Solutions responsible for the growth of the company’s information assets, delivery of innovative offerings for commercial operations, and development of leading-edge database management, patient engagement and end-user technology solutions. With more than two decades of service at IMS Health and its predecessor companies, Kevin has held a variety of senior financial, operations, marketing and general management posts. His roles include serving as senior vice president, Supply Management, senior vice president, Pharma Business Management, and president, Europe, Middle East and Africa. Kevin also was chief financial officer for both IMS Health North America and Europe, and senior vice president, Marketing and Major Markets, EMEA.

Kevin holds a bachelor of science degree in Economics and Accounting from the College of the Holy Cross, and an MBA from New York University’s Stern Business School.

Kevin Knightly

Nilton Paletta is the current President of [IQVIA](/org/iqvia)'s LATAM region. Nilton has held various positions at [IQVIA](/org/iqvia) over the years, and has been with the company since 2006.

They work with Chris Smyth - President - [IQVIA](/org/iqvia) Biotech, Wendy Stewart - President - Clinical Operations, and Ron Bruehlman - EVP & CFO. Their manager is Ari Bousbib, Chairman & CEO.

Nilton Paletta

Jim Berkshire is the Senior Vice President of Business Operations at [IQVIA](/org/iqvia). Jim has over 20 years of experience in the field of information technology and has been with [IQVIA](/org/iqvia) since 1998. In their current role, they are responsible for the development and implementation of a multi-year information technology strategy. Jim also oversees and participates in technology- and innovation-related projects. Prior to joining [IQVIA](/org/iqvia), Jim worked for IMS Health for 19 years, where they held various positions including Vice President Technology Strategy & Planning. In this role, they were responsible for initiating, overseeing and participating in technology- and innovation-related projects. Jim also defined project scope, objectives, deliverables and deadlines for completion; developed project targets, identifed staffing requirements, and selected/managed project teams. Jim has a proven track record of driving change and optimizing costs while creating world-class technology capabilities and an organization that supports IMS’s strategy to reposition itself in a broader market space.

Jim Berkshire has a BA in Economics from Indiana University Bloomington. Jim also has minors in Computer Science and Mathematics.

Jim Berkshire works with Nilton Paletta - President - LATAM, Ronan Brown - SVP, Head of Patient Centric Solutions & Decentralized Trials, and Trudy Stein - EVP, CHRO. Their manager is Ari Bousbib, Chairman & CEO.

Jim Berkshire

Eric Sherbet is the EVP of General Counsel at [IQVIA](/org/iqvia). Prior to joining [IQVIA](/org/iqvia), they served as General Counsel for Patheon from November 2014 to November 2017. Eric has also served as General Counsel for inVentiv Health from April 2011 to October 2014 and as VP, Deputy General Counsel and Corporate Secretary for Foster Wheeler from December 2007 to March 2011. In addition, they were the VP-Law and Corporate Secretary for Avaya Inc. from January 2000 to December 2007. Prior to that, they were a Senior Associate in the Corporate Law Department at [Paul Hastings](/org/paul-hastings-llp) from September 1996 to July 2000. Eric began their career as an Associate at [Willkie Farr & Gallagher LLP](/org/willkie-farr-gallagher-llp) from September 1995 to September 1996. Eric also worked as an Audit Manager at KPMG Peat Marwick from September 1986 to August 1992.

Eric Sherbet pursued a Juris Doctor at New York University School of Law and a BS Commerce in Accounting at the [University of Virginia](/org/university-of-virginia). Eric also attended West Windsor Plainsboro HS.

They work with Nilton Paletta - President - LATAM, Brian O'Dwyer - CEO, Q2 Solutions, and Sanjay Chikarmane - Chief Product Officer. Eric Sherbet reports to Ari Bousbib, Chairman & CEO.

Eric Sherbet

Jon Resnick is the current President - US & Canada at [IQVIA](/org/iqvia). Prior to this role, they served as the President, Real World & Analytics Solutions and before that, the President, Real-World Insights. Jon has been with [IQVIA](/org/iqvia) for over 8 years in various leadership roles. 

Resnick has been instrumental in [IQVIA](/org/iqvia)'s success in real-world data, analytics, technology and consulting services for the healthcare, life science, payer and provider markets. Jon has a proven track record of leading strategic business expansion through organic growth and innovative offering development. 

Jon is known for their ability to cultivate relationships with client executive leaders to understand needs and develop strategic partnerships to build customized solutions. Under their leadership, [IQVIA](/org/iqvia) has achieved double digit revenue and EBITDA growth.

Jon Resnick has a Master of Business Administration (MBA) from Northwestern University - Kellogg School of Management and a Bachelor of Arts - BA in Political Science from [Union College](/org/union-college).

Jon Resnick reports to Ari Bousbib, Chairman & CEO. Jon Resnick works with Gregg Dearhammer - SVP, Data Sciences, Safety & Medical (DSSM), Trudy Stein - EVP, CHRO, and Jeffrey Spaeder - Chief Medical & Scientific Officer.

Jon Resnick

Gregg Dearhammer is the Senior Vice President of Data Sciences, Safety & Medical (DSSM) at [IQVIA](/org/iqvia). Gregg has over 25 years of experience in the biomedical and pharmaceutical industries. 

Dearhammer began their career as a data manager at Abbott Laboratories in 1993. Gregg then spent 10 years at Kendle International, where they rose to the position of Vice President of Biometrics. In 2006, they joined i3 / inVentiv Health as President. Gregg served in this role for eight years before being appointed Chief Operating Officer of inVentiv Health Clinical in 2014. Gregg held this position for two years before joining [IQVIA](/org/iqvia) in 2016. 

Dearhammer has a proven track record of success in leading and growing organizations. Gregg has played a key role inIQVIA’s transformation into a leading provider of data-driven insights and solutions for the biopharmaceutical industry.

Gregg Dearhammer graduated from [Loyola University Chicago](/org/loyola-university-chicago) and then attended St. James.

Gregg Dearhammer reports to Ari Bousbib, Chairman & CEO. Some of their coworkers include Alistair Grenfell - President - EMEA & South Asia, Chris Smyth - President - [IQVIA](/org/iqvia) Biotech, and Cynthia Verst - President - Design & Delivery Innovation.

Gregg Dearhammer

Rob Kotchie is the current President of Real World Solutions at [IQVIA](/org/iqvia). Prior to this position, they served as the SVP & GM of Real World Evidence Solutions from January 2018 to June 2019. Kotchie has also been with IMS Health for many years, serving as Vice President of Real World Evidence Solutions from June 2014 to December 2017, Chief of Staff from July 2012 to June 2014, and Principal of Health Economics & Outcomes Research from September 2002 to July 2012. Rob began their career as a Business Analyst (EMEA) at ZS Associates from July 2001 to September 2002.

Rob Kotchie has a Masters in Science from the [London School of Economics and Political Science](/org/london-school-of-economics-and-political-science) in International Health Policy & Health Economics as well as a MChem from the [University of Oxford](/org/university-of-oxford) in Chemistry.

Some of their coworkers include Cynthia Verst - President - Design & Delivery Innovation, Norihiko Minato - President - Japan, and Ron Bruehlman - EVP & CFO. Rob Kotchie reports to Ari Bousbib, Chairman & CEO. Some individuals on their team include David Thornton - VP, EMEA Biotech, Christina Mack - Chief Scientific Officer - Real World Solutions.

Rob Kotchie

Stéphanie is currently a Key Account Manager at [IQVIA](/org/iqvia). Stéphanie has a PhD from [UC Berkeley](/org/uc-berkeley), where their dissertation research focused on bacterial interactions with the ocular surface. Stéphanie has implemented novel bacterial labeling techniques and showed that the healthy murine cornea lacks resident bacteria, unlike all other exposed tissue. This constitutive state requires IL-1R and MyD88 signaling. Stéphanie has also conducted research on the ocular surface's ability to prevent bacterial colonization. Stéphanie has a degree from [Tufts University](/org/tufts-university) and is originally from France.

Stéphanie's educational career began with a vision science program at the University of California, Berkeley. Stéphanie then went on to earn a Bachelor of Science (B.S.) in biology from [Tufts University](/org/tufts-university) in Medford, MA. Stéphanie is currently enrolled in a vision science program at the University of California, Berkeley.

Stéphanie

Andrew Caruso

shafali jain

Shawn Foley

Derek Rinehart

Urška Vracun

germaine tan

Michael Lee

Milan Novakovic

Sol Anwar

Colleen Goggins has served as a director of [IQVIA](/org/iqvia) since July 2017. Ms. Goggins spent three decades with [Johnson & Johnson](/org/johnson-johnson), a global healthcare company, in a variety of executive and operational roles of increasing responsibility. From 2001 until her retirement in 2011, she served on [Johnson & Johnson](/org/johnson-johnson)'s Executive Committee and as Worldwide Chairman of the Consumer Group, providing strategic leadership for a fully-integrated personal and healthcare portfolio which included many leading brands. Ms. Goggins serves as a member of the supervisory board for Bayer AG and a member of the board of directors for [TD Bank Group](/org/td-bank). She was formerly a director of Valeant Pharmaceuticals International Inc. and served on the Supervisory Board for Krauss-Maffei Corporation. Ms. Goggins is also a member of the [University of Wisconsin Foundation](/org/university-of-wisconsin-foundation) and is a member of the board of directors of the [University of Wisconsin](/org/university-of-wisconsin-madison) Center for Brand and Product Management, the Child Health Institute of New Jersey, the Institute of International Education, and New York City Meals-on-Wheels. Ms. Goggins has a master’s degree in Management, with a concentration in Marketing and Finance, from the Kellogg School of Management, Northwestern University and a bachelor’s of science degree in Food Chemistry from the [University of Wisconsin](/org/university-of-wisconsin-madison). Ms. Goggins serves as a member of the Audit Committee and as a member of the Nominating and Governance Committee.


Colleen Goggins

Ms. Burt has been a principal of Burt-Hilliard Investments since 2008. She also serves on the operating council and as a senior advisor to Consonance Capital Partners, a private equity firm focused on investing in the U.S. healthcare industry, which she joined in 2013. From 1997 to 2007, Ms. Burt was an executive officer of WellPoint, Inc. (now Anthem, Inc.), lastly as Senior Vice President, Corporate Finance and Development. From 1996 to 1997, Ms. Burt was Senior Vice President and Treasurer of [American Medical Response](/org/american-medical-response). From 1981 to 1996, Ms. Burt held various positions at Chase Securities (now J.P. Morgan), lastly as founder, managing director and head of its Health Care Investment Banking Group. Ms. Burt currently serves on the board of directors of ResMed Inc. and WellDyneRx, LLC. She previously served on the boards of directors of [Envision Healthcare](/org/envisionhealth), WellCare Health Plans, Inc., Vanguard Health Systems, Inc. and Transitional Hospitals Corporation. Ms. Burt is a member of Women Corporate Directors. She most recently served as Chair of the Fortune 1000 Working Group for the Women’s Leadership Foundation of Colorado and is currently Chair of the board for the Colorado Chapter of [The Nature Conservancy](/org/the-nature-conservancy). Ms. Burt earned a Bachelor of Business Administration from the [University of Houston](/org/university-of-houston), where she graduated magna cum laude.


Carol J. Burt

Costa Panagos is president, Research and Development Operations, responsible for the global delivery and customer experience of all [IQVIA](/org/iqvia)’s clinical development operations. He oversees a variety of delivery models including traditional full-service studies, virtual trials, and flexible staffing arrangements, while also advocating for increased use of innovative technologies and [IQVIA](/org/iqvia) CORE-enabled solutions to improve operational efficiencies.  

Costa was recently chief executive officer of Q2 Solutions, the joint venture between [IQVIA](/org/iqvia) and Quest Laboratories.  Under his leadership, Q2 Solutions became a leading global clinical trials laboratory services organization which includes Central Laboratory, Genomics, and BioAnalytical and ADME operations.  During his more than 20-year career at [IQVIA](/org/iqvia), Costa has held several senior clinical and commercial leadership roles, including senior vice president and global head of [IQVIA](/org/iqvia)’s Global Laboratories as well as leading its Global Sales Operations organization. Prior to [IQVIA](/org/iqvia), Costa held various roles in the pharmaceutical division of [Bayer](/org/bayer).

Costa earned a bachelor's degree in biology from [Brown University](/org/brown-university) and an MBA from the Booth School of Business, University of Chicago.

Costa Panagos

Ari Bousbib is chairman and chief executive officer of [IQVIA](/org/iqvia). Formed through the merger of IMS Health and Quintiles, [IQVIA](/org/iqvia) offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. [IQVIA](/org/iqvia)’s approximately 55,000 employees conduct operations in more than 100 countries. Ari assumed this position in October 2016 following the merger of Quintiles and IMS Health. From 2010 until the merger, he served as chairman and CEO of IMS Health, leading the company’s IPO in 2014.

Prior to Ari’s appointment at IMS Health, he spent 14 years at United Technologies Corporation (UTC), where he held several senior leadership positions. He joined UTC in 1997 as chief strategy and development officer, became chief operating officer of Otis Elevator Company in 2000, and president and chief executive of Otis in 2002. In 2008, Ari was appointed president of UTC Commercial Companies with executive leadership responsibility for the worldwide operations of Otis, Carrier, UTC Fire and Security and UTC Power, generating $36 billion in annual revenues and leading a team of 150,000 employees around the world.

Ari is a former partner at global management and technology consulting firm [Booz Allen Hamilton](/org/booz-allen-hamilton). He joined the firm in 1987 as an associate and was elected to its partnership in 1992.

Ari has been serving on the board of directors of [The Home Depot](/org/the-home-depot) since 2007, and is a member of the Harvard Medical School Health Care Policy Advisory Council.

Ari Bousbib

Rene Lorenz is Senior Vice President and Chief Business Officer for the Research & Development Solutions organization at [IQVIA](/org/iqvia).
 
With more than 14 years as a biopharmaceutical industry executive, Rene has a proven track record in sales, sales operations, deal negotiations and finance. Rene is responsible for global sales, sales & business operations, pricing & negotiations for the R&D business to help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights.
 
Before being appointed as Senior Vice President and Chief Business Officer in 2016, Rene held several senior leadership positions in sales, finance, R&D operations and global business operations. Prior to joining Quintiles, Rene held various executive leadership roles in sales, finance, administration and general management over his 23 year tenure at IBM.
 
Rene has a dual major in Chemistry and Microbiology from the [University of Miami](/org/university-of-miami) and an Executive MBA in Finance & Management from the Crummer School of Business, [Rollins College](/org/rollins-college).

Rene Lorenz

Ron Bruehlman is executive vice president and chief financial officer for [IQVIA](/org/iqvia). He is responsible for company finance operations, including corporate accounting, financial planning and analysis, internal audit, tax, treasury, investor relations, corporate development, insurance, and the real estate and procurement functions.

Ron is a senior finance leader with 35 years of experience with both public and private companies in the industrial, healthcare services, and petroleum industries. He was previously the Chief Financial Officer of IMS Health from 2011 until the merger of IMS Health and Quintiles in 2016 when he became a senior advisor to the CEO, playing an active role in the integration supporting the executive leadership team. Prior to joining IMS and [IQVIA](/org/iqvia) Ron spent 23 years with United Technologies Corporation (UTC), where he held multiple senior finance leadership roles of increasing responsibility. These included leading the finance function at UTC Commercial, Chief Financial Officer of Carrier Corporation, heading the corporate financial planning and analysis function for UTC and leading UTC’s investor relations function.

Ron currently serves as Chairman of the Board of Directors at Q2 Solutions, the [IQVIA](/org/iqvia) and [Quest Diagnostics](/org/quest-diagnostics) joint venture. 

Ron holds a BS in Economics from the [University of Delaware](/org/university-of-delaware), as well as an MBA from the University of Chicago. 

Ron Bruehlman

David Thornton leads an executive team managing IQVIAs engagements with customer across Europe, providing an agile way for innovators to reach their drug development and commercialization milestones. 

David Thornton

Jeffrey Spaeder

Cynthia Verst

Brian Mi, president, Asia Pacific at [IQVIA](/org/iqvia), leads operations in Greater China, Australia, Korea, and eight Southeast Asia countries.

Brian joined IMS Health in 2008, and during his tenure has served in key leadership positions with increasing responsibilities, including senior principal of IMS Consulting Group, general manager of IMS Greater China, president of IMS China and Southeast Asia, and president of [IQVIA](/org/iqvia) Greater China.

Prior to [IQVIA](/org/iqvia), Brian held management roles at [Pfizer](/org/pfizer) and Amylin Pharmaceuticals, with focus on portfolio planning, new product marketing, R&D strategy and business development.

Brian holds a PhD in pharmaceutical chemistry from Ohio State University and an MBA from the University of Chicago Booth School of Business.

Brian Mi

Alistair Grenfell is president, Europe, Middle East, Africa and South Asia for [IQVIA](/org/iqvia), the Human Data Science Company™, which was created following the merger of Quintiles and IMS Health. In this role, he is responsible for operations in the UK&I, Northern Europe, France, Spain, Portugal & Turkey, Germany & Austria, Switzerland & Israel, Italy & Greece, East Europe, Russia & CIS and Africa, Middle East & South Asia.

Previously, Alistair served as the company’s president, North Europe, Middle East, Africa and South Asia from May 2015 to December 2019. Prior to that role, he was president, North Europe and Africa, from December 2011 to April 2015. He served from 2010 to 2011 as general manager for Belgium, Netherlands, Nordics and Baltics, and before that led the IMS Health sales function in EMEA for three years. Since joining IMS Health in 1996, Alistair has held sales, client services and business management roles spanning Europe, the Middle East and Africa.

Alistair Grenfell

Zairan Liu

Sanjay Chikarmane is the Chief Product Officer for IQVIA. He is responsible for the development and deployment of our end-user software applications across our clinical and commercial businesses.

Sanjay has more than 30 years of experience leading development and product management teams, as well as general management of product-focused businesses for global enterprise software and technology companies. Prior to joining the company, he served as Chief Product Officer and General Manager at Hitachi Vantara Corporation.  While at Hitachi, he led the company’s transition to a software-focused company, leading its SaaS-based enterprise software portfolio which comprised Data Management, Analytics and Industrial IOT solutions. Prior to this he held several executive leadership roles with Illumina, SAP and BEA Systems (acquired by Oracle). 

Sanjay holds a bachelor’s degree in Electrical Engineering from the Indian Institute of Technology, and a master’s degree in Computer Engineering from Syracuse University.

Sanjay Chikarmane

Brian O’Dwyer is chief executive officer of Q2 Solutions. Previously, Brian was vice president and general manager of the Americas region for Q2 Solutions, where he was responsible for all operational activity in North and South America.

Brian has more than 22 years of experience in the healthcare and laboratory industry and has broad experience in the establishment, management, integration and restructuring of both business and commercial operations across the clinical research spectrum. Prior to [IQVIA](/org/iqvia), Brian served as senior vice president of the Eurofins Scientific central laboratory business. Brian also was the senior vice president of Global Bioanalytical Services at ICON having previously led ICON’s Early Phase Clinical division in Europe and served as their group financial controller.

Brian holds a bachelor’s degree in business studies from [Dublin City University](/org/dublin-city-university), Ireland, and is a professionally Certified Management Accountant.

Brian O'Dwyer

Jovan Willford is the SVP and GM of US Commercial Solutions. Jovan has held various leadership roles at [IQVIA](/org/iqvia), including SVP and Global Head of Clinical FSP and VP of Merger Integration. 

Jovan Willford

Nick Childs

Mira Mrcela

John P. Connaughton has served as a director of [IQVIA](/org/iqvia) since October 2016. Prior to this, Mr. Connaughton served as a director of Quintiles since January 2008. Since 1997, Mr. Connaughton has been a Managing Director of [Bain Capital](/org/bain-capital). Prior to [Bain Capital](/org/bain-capital), which he joined in 1989, Mr. Connaughton was a consultant at Bain & Company, Inc., where he worked in the healthcare, consumer products and business services industries. He also serves as a director of iHeartMedia, Inc., a global media and entertainment company, Air Medical Group Holdings, Inc., a provider of air medical services, Bio Products Laboratory, a United Kingdom based producer of plasma products, Grupo Notre Dame Intermedica, a Brazil based healthcare provider, and The Boston Celtics, a National Basketball Association franchise. Mr. Connaughton was formerly a director of SunGard Data Systems Inc., a software and technology services company, Warner Music Group Corp., a music based content company, Warner Chilcott plc, an international pharmaceutical company, HCA Holdings, Inc., a corporate operator of hospitals and health systems, and CRC Health Corporation, a provider of treatment and educational programs related to behavioral issues. He also volunteers for a variety of charitable organizations, serving as a member of The Berklee College of Music Board of Trustees and the [University of Virginia](/org/university-of-virginia) McIntire Foundation Board of Trustees. Mr. Connaughton received a bachelor’s of science degree in commerce from the [University of Virginia](/org/university-of-virginia) and an MBA from [Harvard Business School](/org/harvard-business-school), where he was a Baker Scholar. Mr. Connaughton serves as a member of the Leadership Development and Compensation Committee.


John P. Connaughton

James Fasano has served as a director of [IQVIA](/org/iqvia) since October 2016. Prior to this, Mr. Fasano served as a Director of IMS Health from January 2015 until October 2016. He is a Managing Director responsible for leading CPP Investment Board’s Funds, Secondaries & Co-investments group and previously led CPPIB’s Principal Investing group. Prior to joining CPPIB in 2004, Mr. Fasano worked in the Investment Banking group at Merrill Lynch & Co., focusing on companies in the media and telecommunications sectors. Previously, he was a member of the Mergers & Acquisitions group at [RBC Capital Markets](/org/rbc-capital-markets) and was a Commissioned Officer in the Canadian Armed Forces. Mr. Fasano serves on the boards of directors of NEWAsurion and Cequel Communications, and formerly was a director of AWAS Aviation Capital, LHP Hospital Group and Kinetic Concepts. He has a bachelor’s of Engineering degree from the Royal Military College of Canada and an MBA from the University of Chicago Graduate School of Business. Mr. Fasano chairs the Audit Committee.


James A. Fasano

John G. Danhakl has served as a director of [IQVIA](/org/iqvia) since October 2016. Prior to this, Mr. Danhakl served as a Director of IMS Health from February 2010 until October 2016. He is a Managing Partner at LGP, which he joined in 1995. Previously, Mr. Danhakl was a Managing Director of Donaldson, Lufkin & Jenrette Securities Corporation, which he joined in 1990. From 1985 until 1990, he was a Vice President in corporate finance at Drexel Burnham Lambert, Inc. Mr. Danhakl currently serves on the boards of directors of the following publicly traded companies: Savers, Inc., J. Crew Group, Inc., Petco Animal Supplies, Inc. and Arden Group, Inc. He previously served as a director of Big 5 Sporting Goods Corporation, Communications & Power Industries, Diamond Triumph Auto Glass, Inc., Liberty Group Publishing, Inc., MEMC Electronic Materials, Inc., Phoenix Scientific, Inc., Rite Aid Corporation, VCA Antech, Inc., Air Lease Corporation and The Neiman Marcus Group, Inc. Mr. Danhakl holds a bachelor of arts in Economics from the University of California at Berkeley, and an MBA from [Harvard Business School](/org/harvard-business-school). Mr. Danhakl serves as a member of the Nominating and Governance Committee.


John G. Danhakl

Todd B. Sisitsky has served as a director of [IQVIA](/org/iqvia) since October 2016. Prior to that, Mr. Sisitsky served as a director of IMS Health since February 2010. He is a Partner of TPG where he leads the company’s investment activities in the healthcare sector globally. Mr. Sisitsky serves on the board of directors of Surgical Care Affiliates, Inc., Aptalis Holdings, Inc., formerly Aptalis Pharma, Inc., IASIS Healthcare Corp., HealthScope Ltd., Immucor Inc. and Par Pharmaceuticals Companies, Inc. and previously served on the boards of Biomet Inc. and Fenwal Inc. He also serves on the board of the Campaign for Tobacco Free Kids, a global not-for-profit organization, and the Dartmouth Medical School Board of Overseers. Prior to joining TPG in 2003, Mr. Sisitsky worked at Forstmann Little & Company and Oak Hill Capital Partners. He has an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated summa cum laude. Mr. Sisitsky serves as a member of the Leadership Development and Compensation Committee and as a member of the Nominating and Governance Committee.


IQVIA

Org chart

Teams

Leadership Team

CEO and Executive Team

Board of Directors

Discover similar companies